NCT01949818Unknown4 期
A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma
Mingzhi Zhang1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Progression-free survival
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time > 3 months Histological confirmed Diffuse large B cell lymphoma(III/IV) None of chemotherapy or radiotherapy has been previously used None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L At least one measurable lesion None of other serious diseases, cardiopulmonary function is normal Pregnancy test of women at reproductive age must be negative Patients could be followed up None of other relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic treatments.
排除标准
- •Disagreement on blood sample collection Patients allergic of any of drug in this regimen or with metabolic disorder Pregnant or lactating women Serious medical illness likely to interfere with participation Serious infection Primitive or secondary tumors of central nervous system Chemotherapy or radiotherapy contraindication The evidence of CNS metastasis History of peripheral nervous disorder or dysphrenia patients participating in other clinical trials patients taking other antitumor drugs patients estimated to be unsuitable by investigation
研究组 & 干预措施
Yangzhengxiaoji Capsule combined with CHOP regimen
Experimental
Yangzhengxiaoji Capsule combined with CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
干预措施: Yangzhengxiaoji capsule combined with CHOP regimen (Drug)
CHOP regimen
Experimental
CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
干预措施: CHOP regimen (Drug)
结局指标
主要结局
Progression-free survival
时间窗: up to end of follow-up-phase (approximately 24 months)
次要结局
- overall survival(up to the date of death (approximately 5 years))
研究者
Mingzhi Zhang
The director of oncology department of the first affiliated hospital
Zhengzhou University
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie CapsuleFibrocystic Disease of BreastNCT02929420First Affiliated Hospital Xi'an Jiaotong University600
招募中
4 期
Effect of Yangxinshi Tablet on Exercise Tolerance in Patients With Chronic Coronary Syndrome（MET STUDY）Chronic Coronary SyndromeNCT05978089Dongzhimen Hospital, Beijing120
Unknown
3 期
Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPDPulmonary Disease, Chronic ObstructiveNCT03745261Henan University of Traditional Chinese Medicine240
Unknown
3 期
Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary AdenocarcinomaCancerNCT02929693Shanghai University of Traditional Chinese Medicine198
招募中
4 期
Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral HemorrhageCognitive ImpairmentIntracerebral HemorrhageNCT06673602Qinhuangdao Hospital of Traditional Chinese Medicine200